AR073651A1 - Formulaciones galenicas de compuestos organicos - Google Patents
Formulaciones galenicas de compuestos organicosInfo
- Publication number
- AR073651A1 AR073651A1 ARP090103629A ARP090103629A AR073651A1 AR 073651 A1 AR073651 A1 AR 073651A1 AR P090103629 A ARP090103629 A AR P090103629A AR P090103629 A ARP090103629 A AR P090103629A AR 073651 A1 AR073651 A1 AR 073651A1
- Authority
- AR
- Argentina
- Prior art keywords
- dosage form
- oral dosage
- solid oral
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente se refiere a formulaciones galénicas, en donde el ingrediente activo de alisquireno, de preferencia una sal de hemifumarato del mismo, solo o en combinacion con otro ingrediente activo, se granula por fusion, y está presente en una cantidad de más del 20 por ciento en peso, basándose en el peso total de la forma de dosificacion oral, así como a un proceso para la preparacion de esta forma de dosificacion oral solida. Reivindicacion 6: Una forma de dosificacion oral solida de acuerdo con cualquiera de las reivindicaciones anteriores, en donde el alisquireno se puede obtener mediante la granulacion de fusion con uno o más polímeros. Reivindicacion 20: Una forma de dosificacion oral solida de acuerdo con cualquiera de las reivindicaciones anteriores, en donde la forma de dosificacion comprende además valsartan, o una sal farmacéuticamente aceptable del mismo. Reivindicacion 22: Una forma de dosificacion oral solida de acuerdo con las reivindicaciones 20 o 21, en la forma de una tableta de dos capas, la cual comprende una capa que comprende alisquireno, o una sal farmacéuticamente aceptable del mismo, y una capa que comprende valsartan, o una sal farmacéuticamente aceptable del mismo. Reivindicacion 23: Una forma de dosificacion oral solida de acuerdo con cualquiera de las reivindicaciones 20 a 22, en donde el valsartan, o una sal farmacéuticamente aceptable del mismo, se puede obtener en la forma de un granulado, mediante compactacion con rodillo. Reivindicacion 25: Una forma de dosificacion oral solida de acuerdo con cualquiera de las reivindicaciones anteriores, para el tratamiento de hipertension, insuficiencia cardíaca congestiva, angina, infarto de miocardio, ateroesclerosis, nefropatía diabética, miopatía cardíaca diabética, insuficiencia renal, enfermedad vascular periférica, hipertrofia de ventrículo izquierdo, disfuncion cognitiva, embolia, dolor de cabeza, e insuficiencia cardíaca cronica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9959508P | 2008-09-24 | 2008-09-24 | |
| US16179909P | 2009-03-20 | 2009-03-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073651A1 true AR073651A1 (es) | 2010-11-24 |
Family
ID=41323516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090103629A AR073651A1 (es) | 2008-09-24 | 2009-09-22 | Formulaciones galenicas de compuestos organicos |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20110177166A1 (es) |
| EP (1) | EP2328562A1 (es) |
| JP (1) | JP2012503665A (es) |
| KR (1) | KR20110063684A (es) |
| CN (1) | CN102164584A (es) |
| AR (1) | AR073651A1 (es) |
| AU (1) | AU2009296718A1 (es) |
| BR (1) | BRPI0919077A2 (es) |
| CA (1) | CA2736259A1 (es) |
| CL (1) | CL2011000614A1 (es) |
| CO (1) | CO6351712A2 (es) |
| EC (1) | ECSP11010998A (es) |
| MA (1) | MA32722B1 (es) |
| MX (1) | MX2011003077A (es) |
| PE (1) | PE20110925A1 (es) |
| RU (1) | RU2011116122A (es) |
| TW (1) | TW201016210A (es) |
| WO (1) | WO2010036686A1 (es) |
| ZA (1) | ZA201101686B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110130491A (ko) * | 2009-03-20 | 2011-12-05 | 노파르티스 아게 | 발사르탄 및 알리스키렌의 고정 용량 조합물의 생약 제형 |
| EP2382967A1 (de) * | 2010-04-21 | 2011-11-02 | ratiopharm GmbH | Aliskiren in Form einer festen Dispersion |
| TWI736135B (zh) * | 2013-03-01 | 2021-08-11 | 美商英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途 |
| FR3055800B1 (fr) * | 2016-09-15 | 2020-06-26 | Unither Pharmaceuticals | Composition solide a ingestion rapide et deglutition facilitee, sous forme de particules solides non agglomerees, comprenant deux differents types de particules |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20142101A1 (es) * | 2004-03-17 | 2014-12-27 | Novartis Ag | Composiciones farmaceuticas de aliskiren |
| AR050615A1 (es) * | 2004-08-27 | 2006-11-08 | Novartis Ag | Composiciones farmaceuticas para la administracion oral |
| US20080075772A1 (en) * | 2006-04-13 | 2008-03-27 | Lawrence Solomon | Pharmaceutical compositions having novel scoring patterns and methods of using those compositions |
| AU2007323465B2 (en) * | 2006-11-07 | 2011-08-04 | Novartis Ag | Crystalline forms of aliskiren hemifumarate |
| EP1972335A1 (en) * | 2007-03-23 | 2008-09-24 | Krka | Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof |
| WO2009040427A1 (en) * | 2007-09-28 | 2009-04-02 | Novartis Ag | Galenical formulations of organic compounds |
| AR066168A1 (es) * | 2007-09-28 | 2009-07-29 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
| EP2062874B1 (en) * | 2007-11-20 | 2014-12-17 | KRKA, tovarna zdravil, d.d., Novo mesto | Process and intermediates for the preparation of aliskiren |
-
2009
- 2009-09-22 AR ARP090103629A patent/AR073651A1/es unknown
- 2009-09-23 BR BRPI0919077A patent/BRPI0919077A2/pt not_active IP Right Cessation
- 2009-09-23 EP EP09792885A patent/EP2328562A1/en not_active Withdrawn
- 2009-09-23 US US13/120,182 patent/US20110177166A1/en not_active Abandoned
- 2009-09-23 AU AU2009296718A patent/AU2009296718A1/en not_active Abandoned
- 2009-09-23 WO PCT/US2009/057993 patent/WO2010036686A1/en active Application Filing
- 2009-09-23 KR KR1020117009209A patent/KR20110063684A/ko not_active Application Discontinuation
- 2009-09-23 RU RU2011116122/15A patent/RU2011116122A/ru not_active Application Discontinuation
- 2009-09-23 CA CA2736259A patent/CA2736259A1/en not_active Abandoned
- 2009-09-23 CN CN2009801373641A patent/CN102164584A/zh active Pending
- 2009-09-23 MX MX2011003077A patent/MX2011003077A/es not_active Application Discontinuation
- 2009-09-23 JP JP2011529177A patent/JP2012503665A/ja active Pending
- 2009-09-23 TW TW098132133A patent/TW201016210A/zh unknown
- 2009-09-23 PE PE2011000667A patent/PE20110925A1/es not_active Application Discontinuation
-
2011
- 2011-03-04 ZA ZA2011/01686A patent/ZA201101686B/en unknown
- 2011-03-23 CL CL2011000614A patent/CL2011000614A1/es unknown
- 2011-03-25 CO CO11036970A patent/CO6351712A2/es not_active Application Discontinuation
- 2011-04-20 MA MA33785A patent/MA32722B1/fr unknown
- 2011-04-21 EC EC2011010998A patent/ECSP11010998A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201016210A (en) | 2010-05-01 |
| ECSP11010998A (es) | 2011-06-30 |
| CA2736259A1 (en) | 2010-04-01 |
| JP2012503665A (ja) | 2012-02-09 |
| CN102164584A (zh) | 2011-08-24 |
| WO2010036686A1 (en) | 2010-04-01 |
| KR20110063684A (ko) | 2011-06-13 |
| BRPI0919077A2 (pt) | 2015-12-15 |
| AU2009296718A1 (en) | 2010-04-01 |
| CL2011000614A1 (es) | 2011-11-04 |
| ZA201101686B (en) | 2012-01-25 |
| MA32722B1 (fr) | 2011-10-02 |
| EP2328562A1 (en) | 2011-06-08 |
| CO6351712A2 (es) | 2011-12-20 |
| RU2011116122A (ru) | 2012-10-27 |
| US20110177166A1 (en) | 2011-07-21 |
| PE20110925A1 (es) | 2012-01-13 |
| MX2011003077A (es) | 2011-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066168A1 (es) | Formulaciones galenicas de compuestos organicos | |
| PE20150710A1 (es) | Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion | |
| AR075179A1 (es) | Formulaciones galenicas de compuestos organicos que comprenden alisquireno | |
| GT201200164A (es) | "nuevos compuestos de espiropiperidina" | |
| PE20120585A1 (es) | Forma cristalina del fosfato de dihidrogeno r)-3-(4-(2-(2-metiltetrazol-5-il) piridin-5-il)-3-fluorofensil)-5-hidroximetil oxazolidin-2-ona | |
| CR10455A (es) | Compuestos farmaceuticos | |
| PA8629501A1 (es) | Tabletas dispersables que comprenden un derivado de acido benzoico | |
| CO6382125A2 (es) | Inhibidores de proteína quinasa | |
| PE20100559A1 (es) | Composicion farmaceutica solida que contiene amlodipina y losartan y el proceso para producirla | |
| AR073651A1 (es) | Formulaciones galenicas de compuestos organicos | |
| GT201300309A (es) | Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2- pirimidinil]-amino]-n-[5-(4-metil -1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos | |
| CO6531458A2 (es) | Nuevos compuestos de espiropiperidina | |
| PE20130574A1 (es) | Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa | |
| JP2009537554A5 (es) | ||
| CL2011001848A1 (es) | Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras. | |
| CL2010000059A1 (es) | (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)-3,5-diflurobenzamida o una sal farmaceuticamente aceptable; forma polimorfica de la sal clorhidrato; composicion farmaceutica; y su uso para tratar una enfermedad del sistema nervioso central tal como dolor, sindrome metabolico, inflamacion, alzheimer. | |
| JP2014507476A5 (es) | ||
| Kiriyama et al. | Pharmacokinetic-pharmacodynamic analyses of antihypertensive drugs, nifedipine and propranolol, in spontaneously hypertensive rats to investigate characteristics of effect and side effects | |
| RU2014129508A (ru) | Новая комбинация | |
| CR20120061A (es) | Tableta | |
| JP2013166781A5 (es) | ||
| AR068539A1 (es) | Formulaciones galenicas de compuestos organicos | |
| AR077018A1 (es) | Un comprimido de dosis fija del antagonista del receptor de la trombina y el clopidogrel. | |
| PE20091900A1 (es) | Una formulacion farmaceutica solida | |
| AR084882A1 (es) | Compuesto de 1-azabiciclo[2.2.2]octano y usos para el tratamiento de esquizofrenia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |